We are a well-established drug development company
focused on delivering truly innovative solutions to help
our customers improve their R&D productivity.
Our flexible and adaptive real-time manufacturing approach provides a tailored supply of drug product to specialist oncology clinical trial centers.
Our innovative approach to early development uses Translational Pharmaceutics™ to cut timelines and improve processes, allowing you to reach Proof of Concept far more efficiently.
We have the scientific expertise and operational experience to design and deliver human ADME programs in preparation for NDA/MAA submissions.
All types of drug formulations can be quickly and cost-effectively developed, screened and optimized using our Translational Pharmaceutics™ platform.
Our capabilities in intravenous (IV) formulation development, real-time manufacturing and clinical testing allow us to generate IV pharmacokinetic and absolute bioavailability data, supporting your development programs and regulatory submissions.
Clinical pharmacology programs designed and implemented by us often incorporate additional endpoints, including the effect of food, the effect of age or gender, and pharmacodynamic or biomarker assessments. It is also common to complement a first-in-human to proof-of-concept program with a small patient cohort under a single protocol and regulatory submission.